Prognostic Factors

Specht, Lena; Hasenclever, Dirk

doi:10.1007/978-3-319-12505-3_8

Cited by 4 publications

(6 citation statements)

References 173 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early-stage disease was defined according to the Southwest Oncology Group (SWOG) and Cancer and Leukemia Group B (CALGB) previously published definition (Ann Arbor stage I or II without any B symptoms, infradiaphragmatic presentations, or mediastinal masses greater than one-third the maximum thoracic diameter; ref. 24).…”

Section: Patientsmentioning

confidence: 99%

Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma

Jones

Nourse

Keane

et al. 2014

Clinical Cancer Research

114

View full text Add to dashboard Cite

Purpose: Although microRNAs (miRNA) show potential as diagnostic biomarkers in cancer, their role as circulating cell-free disease response biomarkers remains unknown. Candidate circulating miRNA biomarkers for classical Hodgkin lymphoma (cHL) might arise from Hodgkin-Reed-Sternberg (HRS) cells and/or nonmalignant tumor-infiltrating cells. HRS cells are sparse within the diseased node, embedded within a benign microenvironment, the composition of which is distinct from that seen in healthy lymph nodes.Experimental Design: Microarray profiling of more than 1,000 human miRNAs in 14 cHL primary tissues and eight healthy lymph nodes revealed a number of new disease node-associated miRNAs, including miR-494 and miR-1973. Using quantitative real-time PCR (qRT-PCR), we tested the utility of these, as well as previously identified disease node-associated plasma miRNAs (including miR-21 and miR-155), as disease response biomarkers in a prospective cohort of 42 patients with cHL. Blood samples were taken in conjunction with radiologic imaging at fixed time points before, during, and after therapy. Absolute quantification was used so as to facilitate implementation in diagnostic laboratories.Results: Levels of miR-494, miR-1973, and miR-21 were higher in patients than control (n ¼ 20) plasma (P ¼ 0.004, P ¼ 0.007, and P < 0.0001, respectively). MiR-494 and miR-21 associated with Hasenclever scores !3. Strikingly, all three miRNAs returned to normal at remission (P ¼ 0.0006, P ¼ 0.0002, and P < 0.0001 respectively). However, only miR-494 and miR-1973 reflected interim therapy response with reduction being more pronounced in patients achieving complete versus partial responses (P ¼ 0.043 and P ¼ 0.0012, respectively).Conclusion: Our results demonstrate that in patients with cHL, circulating cell-free miRNAs can reflect disease response once therapy has commenced. Clin Cancer Res; 20(1); 253-64. Ó2013 AACR.

show abstract

Section: Patientsmentioning

confidence: 99%

Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma

Jones

Nourse

Keane

et al. 2014

Clinical Cancer Research

114

View full text Add to dashboard Cite

show abstract

“…This trial was designed as a titration study 11 and recruited at 186 hospital sites across 16 European countries (Czech Republic, England, France, Germany, Austria, Ireland, Slovakia, Sweden, Norway, Poland, Belgium, Switzerland, Denmark, Spain, Slovenia, and The Netherlands (appendix pp 2, 5-9). This study recruited patients to three treatment groups on the basis of disease stage and the presence or absence of B symptoms, defined as weight loss, fever, or night sweats, or a combination.…”

Section: Study Design and Participantsmentioning

confidence: 99%

Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study

Mauz‐Körholz¹,

Landman‐Parker²,

Fernández‐Teijeiro³

et al. 2023

The Lancet Oncology

View full text Add to dashboard Cite

“…Isto tako, stejdžing sistem pruža mogućnost da se utvrde pojedini prognozni parametri koji ukazuju na povećani rizik od pojave recidiva bolesti ili su indikator niske stope preživljavanja (93). Do sada je, u skladu sa novim saznanjima, tehnološkim dostignućima i novim terapijskim pristupima, razvijeno i modifikovano nekoliko stejdžing sistema (93).…”

Section: Kliničke Karakteristike I Procena Proširenosti Hlunclassified

“…-postoji mogućnost primene prekomerne terapije, odnosno, koja bi mogla imati korist od redukcije terapije ili -primena standardne terapije najverovatnije neće dovesti do izlečenja i kod kojih je indikovana primena drugih terapijskih pristupa (93). Internacionalni Prognozni Skor će ostati metod izbora za intezivniji terapijski pristup u visoko rizičnih bolesnika sa uznapredovalim stadijumom bolesti sve dok se ne definišu novi, pouzdani, biološki specifični prognozni markeri (93).…”

Section: Hočkinovog Limfomaunclassified

See 1 more Smart Citation

Correlation of clinical parameters with apoptotic biological markers in prognosis of classical Hodgkin lymphoma

Jaković¹

View full text Add to dashboard Cite

Prognostic Factors

Cited by 4 publications

References 173 publications

Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma

Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma

Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study

Correlation of clinical parameters with apoptotic biological markers in prognosis of classical Hodgkin lymphoma

Contact Info

Product

Resources

About